On Nov 03, 2025, NUVB reported earnings of -0.16 USD per share (EPS) for Q3 25, beating the estimate of -0.17 USD, resulting in a 6.98% surprise. Revenue reached 13.12 million, compared to an expected 6.75 million, with a 94.49% difference. The market reacted with a -6.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 36.00 million USD, implying an decrease of -43.75% EPS, and increase of 174.38% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
FAQ
What were Nuvation Bio Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Nuvation Bio Inc. reported EPS of -$0.16, beating estimates by 6.98%, and revenue of $13.12M, 94.49% above expectations.
How did the market react to Nuvation Bio Inc.'s Q3 2025 earnings?
The stock price moved down -6.58%, changed from $5.17 before the earnings release to $4.83 the day after.
When is Nuvation Bio Inc. expected to report next?
The next earning report is scheduled for Mar 04, 2026.
What are the forecasts for Nuvation Bio Inc.'s next earnings report?
Based on 12
analysts, Nuvation Bio Inc. is expected to report EPS of -$0.09 and revenue of $36.00M for Q4 2025.